Current Issue : July-September Volume : 2014 Issue Number : 3 Articles : 1 Articles
The currently available oral therapies for type 2 diabetes all have limitations which mean that patients therapeutic goals may not be easily and safely achieved, even when combinations of drugs are prescribed. New blood glucose lowering therapies that are effective and well tolerated are needed. In the search for potential new drug targets for the treatment of diabetes, Dipepdyle peptidase 4 inhibitors (DPP 4 inhibitors), have been the subject of particular attention. They are weight neutral (do not cause weight gain or loss) and appear to decrease beta-cell apoptosis and increase beta-cell survival. Although theoretical advantages exist for agents with a higher specificity for DPP-4 inhibition versus inhibition of other isoenzymes associated with toxicity, comparative studies and/or increased clinical experience with this class of drug will determine the clinical advantages, if any, of one agent over another. DPP- 4 inhibitors class is very useful in future beacuse less side effect and two difference pathway (Increase insulin and decrease glucagon) acts in diabetes....
Loading....